Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas

NCT03925246 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

High Grade Glioma
Brain Cancer

Interventions

DRUG: Nivolumab

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]